| Year |
Citation |
Score |
| 2024 |
Zheng Y, Lebid A, Chung L, Fu J, Wang X, Otrocol A, Zarif JC, Yu H, Llosa NJ, Pardoll DM. Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy. Oncoimmunology. 13: 2297503. PMID 38235319 DOI: 10.1080/2162402X.2023.2297503 |
0.362 |
|
| 2022 |
Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, Martinez C, Dorff TB, Forman SJ, Priceman SJ. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. Journal For Immunotherapy of Cancer. 10. PMID 35738799 DOI: 10.1136/jitc-2021-004400 |
0.345 |
|
| 2022 |
Miyahira AK, Zarif JC, Coombs CC, Flavell RR, Russo JW, Zaidi S, Zhao D, Zhao SG, Pienta KJ, Soule HR. Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. The Prostate. 82: 169-181. PMID 34734426 DOI: 10.1002/pros.24262 |
0.596 |
|
| 2021 |
Lopez-Bujanda ZA, Obradovic A, Nirschl TR, Crowley L, Macedo R, Papachristodoulou A, O'Donnell T, Laserson U, Zarif JC, Reshef R, Yuan T, Soni MK, Antonarakis ES, Haffner MC, Larman HB, et al. TGM4: an immunogenic prostate-restricted antigen. Journal For Immunotherapy of Cancer. 9. PMID 34193566 DOI: 10.1136/jitc-2020-001649 |
0.596 |
|
| 2021 |
McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, et al. Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. Jco Global Oncology. 7: 495-505. PMID 33835826 DOI: 10.1200/GO.20.00571 |
0.442 |
|
| 2020 |
Rencsok EM, Bazzi LA, McKay RR, Huang FW, Friedant A, Vinson J, Peisch S, Zarif JC, Simmons S, Hawthorne K, Villanti P, Kantoff PW, Heath E, George DJ, Mucci LA. Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32503813 DOI: 10.1158/1055-9965.Epi-19-1616 |
0.44 |
|
| 2020 |
Nirschl TR, El Asmar M, Ludwig WW, Ganguly S, Gorin MA, Johnson MH, Pierorazio PM, Drake CG, Allaf ME, Zarif JC. Transcriptional profiling of tumor associated macrophages in human renal cell carcinoma reveals significant heterogeneity and opportunity for immunomodulation. American Journal of Clinical and Experimental Urology. 8: 48-58. PMID 32211454 |
0.311 |
|
| 2019 |
Simons BW, Kothari V, Benzon B, Ghabili K, Hughes R, Zarif J, Ross AE, Hurley PJ, Schaeffer EM. A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. Oncotarget. 10: 6845-6854. PMID 31839878 DOI: 10.18632/oncotarget.27317 |
0.417 |
|
| 2019 |
Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM. Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. European Urology Oncology. 2: 429-436. PMID 31277779 DOI: 10.1016/J.Euo.2018.09.014 |
0.542 |
|
| 2018 |
Zarif JC, Antonarakis ES. Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. Ame Medical Journal. 3. PMID 30542670 DOI: 10.21037/amj.2018.10.08 |
0.594 |
|
| 2017 |
Sharma A, Mendonca J, Ying J, Kim HS, Verdone JE, Zarif JC, Carducci M, Hammers H, Pienta KJ, Kachhap S. The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. Molecular Oncology. PMID 28371345 DOI: 10.1002/1878-0261.12059 |
0.722 |
|
| 2017 |
Zarif JC, Yang W, Hernandez JR, Zhang H, Pienta KJ. The identification of Macrophage enriched glycoproteins using glycoproteomics. Molecular & Cellular Proteomics : McP. PMID 28348171 DOI: 10.1074/mcp.M116.064444 |
0.363 |
|
| 2016 |
Zarif JC, Miranti CK. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cellular Signalling. 28: 348-56. PMID 26829214 DOI: 10.1016/J.Cellsig.2016.01.013 |
0.766 |
|
| 2015 |
Zarif JC, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget. 6: 6862-76. PMID 25730905 DOI: 10.18632/Oncotarget.3119 |
0.728 |
|
| 2015 |
Shiraishi T, Verdone JE, Huang J, Kahlert UD, Hernandez JR, Torga G, Zarif JC, Epstein T, Gatenby R, McCartney A, Elisseeff JH, Mooney SM, An SS, Pienta KJ. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget. 6: 130-43. PMID 25426557 DOI: 10.18632/Oncotarget.2766 |
0.463 |
|
| 2014 |
Zarif JC, Taichman RS, Pienta KJ. TAM macrophages promote growth and metastasis within the cancer ecosystem. Oncoimmunology. 3: e941734. PMID 25954596 DOI: 10.4161/21624011.2014.941734 |
0.313 |
|
| 2014 |
Yang KR, Mooney SM, Zarif JC, Coffey DS, Taichman RS, Pienta KJ. Niche inheritance: a cooperative pathway to enhance cancer cell fitness though ecosystem engineering. Journal of Cellular Biochemistry. 115: 1478-85. PMID 24700698 DOI: 10.1002/Jcb.24813 |
0.324 |
|
| 2013 |
Zarif JC, Lamb LE, Miranti CK. Abstract 3801: Androgen Receptor non-genomic regulation of prostate tumor cell invasion and metastasis through Src signaling and Matriptase . Cancer Research. 73: 3801-3801. DOI: 10.1158/1538-7445.Am2013-3801 |
0.744 |
|
| 2012 |
Zarif JC, Lamb LE, Miranti CK. Abstract A5: Androgen Receptor non-genomic regulation of invasion and metastasis of prostate tumor cells Cancer Research. 72: A5-A5. DOI: 10.1158/1538-7445.Prca2012-A5 |
0.739 |
|
| 2011 |
Lamb LE, Zarif JC, Miranti CK. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling. Cancer Research. 71: 2739-49. PMID 21310825 DOI: 10.1158/0008-5472.Can-10-2745 |
0.745 |
|
| Show low-probability matches. |